Add BrightSurf on Google Email

Anti-rejection medication and immunotherapy kicks cancer and protects kidney transplants

Researchers at the University of South Australia have discovered that combining anti-rejection medication with immune checkpoint inhibitors can significantly reduce the risk of organ rejection and eliminate cancer cells in a quarter of patients. The study involved 22 patients with renal transplants and incurable locally advanced or met...

SourceUniversity of South Australia·JournalThe Lancet Oncology·TypeExperimental study·DateJul 18, 2022

Genetic discovery to improve lung cancer treatment

Researchers at Edith Cowan University have found a genetic link between human leukocyte antigens and immunotherapy side effects in non-small cell lung cancer patients. The discovery enables doctors to tailor treatment to individual patients, reducing the risk of toxicities and improving overall outcomes.

SourceEdith Cowan University·JournalEuropean Journal of Cancer·TypeRandomized controlled/clinical trial·DateJul 13, 2022

Cleveland Clinic research suggests tumors with specific genetic mutations are sensitive to immunotherapy

Researchers at Cleveland Clinic discovered that pathogenic POLE/POLD1 genetic mutations in tumors lead to a high level of immune cell infiltration and improved response to immune checkpoint blockade therapy. The study's findings contribute to the growing list of discoveries that prove certain classes of drugs are more effective based o...

SourceCleveland Clinic·JournalNature Genetics·DateJul 12, 2022

TCF-1 protein plays essential role in breaking down barriers as T cells form

Researchers discovered that the TCF-1 protein enables plasticity in cells across neighborhoods during T cell development, weakening insulation and increasing interactions between adjacent neighborhoods. This finding sheds new light on immunotherapy approaches and could lead to more efficient cancer treatments.

SourceUniversity of Pennsylvania School of Medicine·JournalNature Immunology·TypeExperimental study·DateJun 20, 2022

Peanut allergy treatment safest when started for infants under 12 months

A new study published in the Journal of Allergy and Clinical Immunology: In Practice found that infants under 12 months who undergo oral immunotherapy have a better safety profile compared to older preschoolers. The treatment, which involves gradually increasing exposure to peanut flour, is highly effective and safe for this age group.

SourceUniversity of British Columbia·JournalJournal of Allergy and Clinical Immunology: In Practice·TypeObservational study·DateJun 16, 2022

NUS Yong Loo Lin School of Medicine and Xiamen University researchers use nanotechnology to destroy and prevent relapse of solid tumour cancers

Researchers at NUS Yong Loo Lin School of Medicine and Xiamen University have developed a novel nanovaccine that achieves complete clearance of solid tumors and induces long-lasting immune memory. The vaccine stimulates anti-tumor immunity by presenting antigens in a way that traditional vaccines cannot.

Studies reveal new insights into gut microbiome impact on immunotherapy response in multiple cancers, including glioblastoma

Researchers at MD Anderson Cancer Center found distinct gut microbiome signatures associated with immunotherapy response in patients with newly diagnosed glioblastoma. The study identified a link between gut microbiome signatures and immune checkpoint blockade response in melanoma, NSCLC, and sarcoma.

Sanoff offers perspective on a promising rectal cancer study in the New England Journal of Medicine

A recent study published in the New England Journal of Medicine found that dostarlimab was effective in treating a subtype of rectal cancer, showing remarkable responses and resolving difficult symptoms. The treatment offers a more effective and less toxic alternative to traditional chemotherapy and radiation.

SourceUNC Lineberger Comprehensive Cancer Center·JournalNew England Journal of Medicine·TypeCommentary/editorial·DateJun 5, 2022

Biomarker in liquid biopsy for lung cancer appears more accurate in predicting immunotherapy response than tumor biopsy

Researchers validated a liquid biopsy test as a better predictor of immunotherapy response in lung cancer patients compared to traditional tumor biopsies. The test measures the PD-L1 biomarker in blood, showing improved accuracy in predicting treatment outcomes and survival.

SourceThe Mount Sinai Hospital / Mount Sinai School of Medicine·JournalJournal of Experimental & Clinical Cancer Research·DateJun 2, 2022

Killing cancers with Z-DNA: A new approach to treating therapy resistant tumors that targets a very-specific cell-death pathway

Scientists have discovered a small molecule that bypasses ADAR1 suppression and directly activates tumor cell death by ZBP1, inducing highly immunogenic cell death and destroying fibroblasts supporting tumor growth. This approach has the potential to improve the effectiveness of immunotherapy in treating therapy-resistant tumors.

SourceInsideOutBio·JournalNature·TypeExperimental study·DateMay 25, 2022

Regulating the regulators of the immune system

Researchers discovered that checkpoint inhibitors can activate regulatory T cells, which can counteract the immune response. Blocking PD-L1 enhanced effector Treg activity, reducing ability to control parasite infections. This finding highlights complexity of immune system's balance between controlling pathogens and protecting healthy ...

SourceUniversity of Pennsylvania·JournalNature Immunology·TypeExperimental study·DateApr 19, 2022

Illumination of immune checkpoint LAG3 ‘black box’ could yield new cancer and autoimmune therapies

Researchers have shed light on how immune checkpoint protein LAG3 modulates T cell activity, providing crucial information for the development of new LAG3-blocking therapies. The study found that LAG3 suppresses T cell activation by disrupting coreceptor-Lck association, even in the absence of MHC Class II molecules.

SourceUniversity of Pittsburgh·JournalNature Immunology·TypeExperimental study·DateApr 18, 2022

Moffitt researchers identify key characteristics of immune cells in ovarian cancer

Researchers at Moffitt Cancer Center have discovered that tissue-resident memory T cells are crucial for recognizing tumor cells in ovarian cancer. These T cells arise from circulating T cells and undergo a differentiation process to target cancer cells, providing a potential roadmap for improved immunotherapy options.

Immunotherapy plus chemotherapy before surgery improves outcomes for lung cancer patients

Adding immunotherapy to chemotherapy before surgery reduced the risk of recurrence and death in lung cancer patients by 37%, according to a phase III trial. The treatment also led to a nearly twelvefold increase in pathological complete response, with 24% of patients achieving no active cancer remaining when the tumor was removed.

SourceJohns Hopkins Medicine·JournalNew England Journal of Medicine·DateApr 11, 2022

Houston Methodist researchers identify an immunotherapy target to combat glioblastomas

Glioblastomas, the deadliest brain cancer, have evaded immune cells by promoting immunosuppressive myeloid cells. Researchers identified S100A4 as a key molecule that can selectively target these immune suppressive cells. This discovery paves the way for new therapeutic strategies to restore antitumor action in glioblastoma patients.

SourceHouston Methodist·JournalNature Communications·TypeExperimental study·DateApr 5, 2022

Ben-Gurion University researchers and colleagues offer new treatment protocol for advanced head and neck cancer

Researchers at Ben-Gurion University have developed a potential treatment combination for advanced head and neck cancer, which shows promise in pre-clinical models. The therapy involves blocking a specific signaling pathway and sensitizing tumors to immunotherapy, resulting in the disappearance of tumors.

SourceBen-Gurion University of the Negev·JournalJournal for ImmunoTherapy of Cancer·TypeExperimental study·DateMar 28, 2022

Penn-Developed CAR T Cells Suppress GI Solid Tumor Cells, Without Toxicity to Healthy Tissue, in Preclinical Research

Researchers at Penn Medicine have discovered a new approach to treat solid cancers using CDH17CAR T cells, which selectively target and eliminate gastrointestinal (GI) solid tumors like gastric, pancreatic, and colorectal cancers in preclinical models. Unlike other immunotherapies, CDH17CAR T cells do not show toxicity to healthy tissues.

Steven A. Rosenberg, MD, PhD, FAACR, recognized with 2022 Pezcoller Foundation-AACR International Award for Extraordinary Achievement in Cancer Research

Dr. Steven A. Rosenberg's pioneering work on IL-2 and its use in treating metastatic melanoma and other cancers led to the FDA approval of first U.S.-born cancer immunotherapy. His subsequent research on CAR T-cell therapy has resulted in promising clinical results for various types of cancer.

Novel therapeutic strategy shows promise against pancreatic cancer

Scientists at Albert Einstein College of Medicine have developed a novel therapeutic strategy that uses bacteria to deliver tetanus toxin into pancreatic tumor cells, inducing an immune response and killing the cancer. The treatment has shown promise in reducing cancer metastases by 87% and increasing mouse lifespan by 40%.

SourceAlbert Einstein College of Medicine·JournalScience Translational Medicine·TypeObservational study·DateMar 23, 2022

FDA approved new immunotherapy regimen for patients with melanoma based on Johns Hopkins Research

The FDA has approved a novel combination therapy of relatlimab and nivolumab for patients with metastatic or inoperable melanoma. The treatment significantly delayed cancer progression time compared to nivolumab alone. LAG-3 blockade reinvigorated T cell anti-tumor activity, establishing the pathway as the third immune checkpoint target.

SourceJohns Hopkins Medicine·JournalNew England Journal of Medicine·DateMar 23, 2022